PubRank

Robert S Hogg

Author PubWeight™ 399.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 19.90
2 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 16.56
3 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009 14.01
4 Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010 12.82
5 Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009 6.03
6 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006 5.00
7 Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011 4.68
8 Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2004 4.55
9 The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ 2011 4.54
10 Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 2003 4.46
11 Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 2003 4.38
12 Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010 3.72
13 The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009 3.67
14 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007 3.46
15 Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008 3.38
16 Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006 3.38
17 Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003 3.19
18 Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010 3.12
19 Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health 2006 3.04
20 Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007 3.04
21 Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med 2008 2.97
22 Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007 2.81
23 Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 2013 2.78
24 Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008 2.77
25 Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS 2002 2.74
26 Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005 2.74
27 Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010 2.65
28 Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ 2004 2.63
29 A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006 2.61
30 When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 2005 2.48
31 Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005 2.42
32 The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007 2.39
33 Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006 2.33
34 The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr 2009 2.31
35 U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 2012 2.18
36 Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ 2003 2.18
37 Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008 2.14
38 Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther 2004 2.14
39 Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. AIDS 2007 2.09
40 AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV 2015 2.09
41 Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada. J Nutr 2005 2.08
42 Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009 2.05
43 Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010 2.04
44 Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr 2002 2.02
45 Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One 2012 2.02
46 Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006 1.98
47 Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting. Am J Public Health 2010 1.95
48 Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr 2008 1.94
49 Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis 2008 1.93
50 Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 2006 1.92
51 Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place 2004 1.90
52 The direct costs of HIV/AIDS care. Lancet Infect Dis 2006 1.87
53 [Estimating the 2006 prevalence of HIV by gender and risk groups in Tijuana, Mexico]. Gac Med Mex 2009 1.86
54 Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008 1.83
55 The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004 1.82
56 Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003 1.77
57 Highly active antiretroviral therapy and increased use of contraceptives among HIV-positive women during expanding access to antiretroviral therapy in Mbarara, Uganda. Am J Public Health 2008 1.77
58 Intensive care unit admission has minimal impact on long-term mortality. Crit Care Med 2002 1.73
59 Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 2013 1.72
60 Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006 1.72
61 Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antivir Ther 2003 1.70
62 Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003 1.69
63 Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010 1.68
64 Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users. Int J Epidemiol 2004 1.67
65 Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One 2010 1.65
66 Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004 1.64
67 Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 2003 1.63
68 Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services. PLoS One 2010 1.63
69 Sexual violence among a cohort of injection drug users. Soc Sci Med 2003 1.61
70 Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend 2007 1.60
71 Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003 1.58
72 Unprotected anal intercourse associated with recreational drug use among young men who have sex with men depends on partner type and intercourse role. Sex Transm Dis 2004 1.56
73 Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011 1.55
74 The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. J Acquir Immune Defic Syndr 2003 1.54
75 Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004 1.51
76 Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011 1.50
77 Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr 2005 1.48
78 Health system determinants of infant, child and maternal mortality: A cross-sectional study of UN member countries. Global Health 2011 1.46
79 Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011 1.46
80 Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J 2005 1.45
81 Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002 1.41
82 CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study. J Acquir Immune Defic Syndr 2003 1.39
83 Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002 1.38
84 Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health 2003 1.38
85 Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Antivir Ther 2003 1.34
86 Impairments, activity limitations and participation restrictions: prevalence and associations among persons living with HIV/AIDS in British Columbia. Health Qual Life Outcomes 2004 1.32
87 Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009 1.32
88 Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS Res Ther 2007 1.30
89 Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS 2005 1.30
90 Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One 2013 1.29
91 Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol 2010 1.27
92 Conversations with mothers: exploring reasons for prevention of mother-to-child transmission (PMTCT) failures in the era of programmatic scale-up in Soweto, South Africa. AIDS Behav 2012 1.26
93 HIV/AIDS in Vancouver, British Columbia: a growing epidemic. Harm Reduct J 2009 1.24
94 Complementary and alternative medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy. Complement Ther Clin Pract 2006 1.23
95 Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. J Infect 2005 1.21
96 Inability to access addiction treatment and risk of HIV infection among injection drug users. J Acquir Immune Defic Syndr 2004 1.21
97 Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis 2011 1.20
98 Determinants of HIV serconversion in an era of increasing HIV infection among young gay and bisexual men. AIDS 2003 1.19
99 Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003 1.18
100 Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. AIDS Patient Care STDS 2012 1.17
101 Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2003 1.17
102 The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 2008 1.16
103 Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS 2011 1.16
104 Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men. Can J Public Health 2005 1.14
105 CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010 1.13
106 Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther 2004 1.12
107 Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011 1.11
108 Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol 2012 1.11
109 Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. CMAJ 2005 1.11
110 Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. Subst Use Misuse 2005 1.10
111 Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005 1.09
112 Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002 1.09
113 Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One 2013 1.09
114 Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting. AIDS Care 2011 1.08
115 Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007 1.08
116 Sexual risk profile of young men in Vancouver, British Columbia, who have sex with men and inject drugs. AIDS Behav 2004 1.08
117 Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS One 2013 1.08
118 Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003 1.07
119 Drug and HIV-related risk behaviors after geographic migration among a cohort of injection drug users. AIDS Behav 2008 1.07
120 Development and validation of a composite programmatic assessment tool for HIV therapy. PLoS One 2012 1.06
121 Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART. AIDS Res Ther 2006 1.06
122 A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010 1.05
123 Non-consensual sex experienced by men who have sex with men: prevalence and association with mental health. Patient Educ Couns 2003 1.05
124 Community mapping and respondent-driven sampling of gay and bisexual men's communities in Vancouver, Canada. Cult Health Sex 2014 1.05
125 Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care (Chic) 2005 1.04
126 The cost of inaction on HIV transmission among injection drug users and the potential for effective interventions. J Urban Health 2004 1.04
127 Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Drug Alcohol Rev 2006 1.04
128 Sexual violence among two populations of men at high risk of HIV infection. AIDS Care 2006 1.04
129 Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004 1.04
130 Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002 1.03
131 The Iranian population is graying: are we ready? Arch Iran Med 2010 1.01
132 Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003 1.01
133 Relationship between food insecurity and mortality among HIV-positive injection drug users receiving antiretroviral therapy in British Columbia, Canada. PLoS One 2013 1.01
134 Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006 1.00
135 Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2005 1.00
136 Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004 0.99
137 HIV incidence and prevalence among aboriginal peoples in Canada. AIDS Behav 2011 0.98
138 HIV antiviral drug resistance: patient comprehension. AIDS Care 2010 0.98
139 Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 2002 0.98
140 Implications for HIV prevention programs from a serobehavioural survey of men who have sex with men in Vancouver, British Columbia: the ManCount study. Can J Public Health 2012 0.96
141 HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011. J Acquir Immune Defic Syndr 2013 0.96
142 Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART. J Int Assoc Physicians AIDS Care (Chic) 2008 0.96
143 Validity of self-reported antiretroviral therapy use among injection drug users. J Acquir Immune Defic Syndr 2006 0.95
144 Prevalence of activity limitation among persons living with HIV/AIDS in British Columbia. Can J Public Health 2004 0.94
145 The WHOMEN's scale (Women's HAART Optimism Monitoring and EvaluatioN Scale v.1) and the association with fertility intentions and sexual behaviours among HIV-positive women in Uganda. AIDS Behav 2009 0.94
146 Epidemiology of antiretroviral multiclass resistance. Am J Epidemiol 2010 0.94
147 Availability of nutritional support services in HIV care and treatment sites in sub-Saharan African countries. Public Health Nutr 2011 0.94
148 Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol 2011 0.93
149 The first ten years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996-2006. Cad Saude Publica 2007 0.93
150 Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 2004 0.92
151 Validity of self-reported adherence among injection drug users. J Int Assoc Physicians AIDS Care (Chic) 2008 0.92
152 Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Res Ther 2011 0.91
153 Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. BMC Infect Dis 2010 0.91
154 High prevalence of smoking among urban-dwelling Canadian men who have sex with men. J Urban Health 2006 0.91
155 Factors associated with disclosure of HIV status among a cohort of individuals on antiretroviral therapy in British Columbia, Canada. AIDS Behav 2014 0.91
156 Sustained increase in HIV-1 incidence since 2000 among men who have sex with men in British Columbia, Canada. J Acquir Immune Defic Syndr 2005 0.90
157 Factors associated with geographic migration among a cohort of injection drug users. Health Place 2007 0.90
158 Epidemiology of treatment failure: a focus on recent trends. Curr Opin HIV AIDS 2009 0.90
159 Randomized clinical evaluation of self-screening for anal cancer precursors in men who have sex with men. Cytojournal 2006 0.90
160 Factors associated with antiretroviral medication adherence among HIV-positive adults accessing highly active antiretroviral therapy (HAART) in British Columbia, Canada. J Int Assoc Physicians AIDS Care (Chic) 2012 0.90
161 Illustrated instructions for self-collection of anorectal swab specimens and their adequacy for cytological examination. Sex Transm Dis 2006 0.89
162 Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003 0.89
163 Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr 2005 0.89
164 Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals. Am J Public Health 2009 0.88
165 Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 2004 0.88
166 Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3. J Infect Dis 2005 0.88
167 Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program. BMC Public Health 2010 0.88
168 HIV Community Viral Load and Factors Associated With Elevated Viremia Among a Community-Based Sample of Men Who Have Sex With Men in Vancouver, Canada. J Acquir Immune Defic Syndr 2016 0.87
169 Editorial: Introduction to the Supplement on HIV, HAART, and Fertility in sub-Saharan Africa. AIDS Behav 2009 0.87
170 Sticking to it: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed. AIDS Behav 2011 0.87
171 Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS 2015 0.87
172 Cohort Profile: Longitudinal Investigations into Supportive and Ancillary health services. Int J Epidemiol 2012 0.87
173 Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005 0.87
174 CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses 2008 0.86
175 Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antivir Ther 2003 0.86
176 The Holy Grail: The search for undiagnosed cases is paramount in improving the cascade of care among people living with HIV. Can J Public Health 2013 0.86
177 Identifying self-perceived HIV-related stigma in a population accessing antiretroviral therapy. AIDS Care 2012 0.86
178 Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients. CMAJ 2005 0.86
179 Regional and temporal trends in migration among people living with HIV/AIDS in British Columbia, 1993-2005. Can J Public Health 2010 0.85
180 Cohort profile: the TASO-CAN Cohort Collaboration. Int J Epidemiol 2011 0.85
181 Deadly public policy: what the future could hold for the HIV epidemic among injection drug users in Vancouver. Curr HIV/AIDS Rep 2012 0.85
182 Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr 2011 0.85
183 Shifting sands: changing regional and gender-specific patterns of HIV/AIDS mortality in Canada, 1987 to 2008. Can J Public Health 2012 0.85
184 Presenting plasma HIV RNA level and rate of CD4 T-cell decline. JAMA 2007 0.85
185 The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS Care 2013 0.85
186 HAART slows progression to anal cancer in HIV-infected MSM. AIDS 2015 0.85
187 The impact of sex partners' HIV status on HIV seroconversion in a prospective cohort of injection drug users. J Acquir Immune Defic Syndr 2006 0.84
188 Acceptability of human papillomavirus vaccination and sexual experience prior to disclosure to health care providers among men who have sex with men in Vancouver, Canada: implications for targeted vaccination programs. Vaccine 2012 0.84
189 Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010. J Acquir Immune Defic Syndr 2014 0.84
190 Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users. Addiction 2007 0.84
191 Intergenerational sex as a risk factor for HIV among young men who have sex with men: a scoping review. Curr HIV/AIDS Rep 2013 0.83
192 Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia. AIDS Behav 2014 0.83
193 Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada. Antivir Ther 2014 0.83
194 Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. AIDS 2014 0.83
195 Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. Pharmacoeconomics 2015 0.83
196 Intensive care unit survivors have fewer hospital readmissions and readmission days than other hospitalized patients in British Columbia. Crit Care Med 2004 0.83
197 Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina. Medscape J Med 2008 0.83
198 Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006. Can J Public Health 2011 0.83
199 Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS 2003 0.83
200 Nitrite inhalant use among young gay and bisexual men in Vancouver during a period of increasing HIV incidence. BMC Public Health 2007 0.83
201 Hungering for HAART. Ann Intern Med 2007 0.83
202 "The way I see it": the effect of stigma and depression on self-perceived body image among HIV-positive individuals on treatment in British Columbia, Canada. AIDS Care 2011 0.82
203 Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina. J Int AIDS Soc 2008 0.82
204 Correlates of suicide attempts in an open cohort of young men who have sex with men. Can J Public Health 2002 0.82
205 Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme. Antivir Ther 2003 0.82
206 Predicting hospitalization among HIV-infected antiretroviral naïve patients starting HAART: determining clinical markers and exploring social pathways. AIDS Care 2008 0.82
207 Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 2002 0.81
208 No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy. AIDS 2002 0.81
209 Trends in antenatal human immunodeficiency virus prevalence in Western Kenya and Eastern Uganda: evidence of differences in health policies? Int J Epidemiol 2004 0.81
210 "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2002 0.81
211 Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. AIDS Care 2010 0.81
212 To stop or not to stop: that is the question, but what is the answer? AIDS 2002 0.81
213 Self-screening for rectal sexually transmitted infections: human papillomavirus. Clin Infect Dis 2006 0.81
214 Rates of inappropriate antiretroviral prescription among injection drug users. Harm Reduct J 2007 0.81
215 Home is where the HAART is: an examination of factors affecting neighbourhood perceptions among people with HIV/AIDS on antiretroviral therapy. AIDS Care 2011 0.81
216 Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011. Med Care 2014 0.80
217 Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Antivir Ther 2009 0.80
218 Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antivir Ther 2005 0.80
219 'It's like the treasure': beliefs associated with semen among young HIV-positive and HIV-negative gay men. Cult Health Sex 2008 0.80
220 The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia. Can J Infect Dis Med Microbiol 2005 0.80
221 Perceptions of HIV and fertility among adolescents in Soweto, South Africa: stigma and social barriers continue to hinder progress. AIDS Behav 2009 0.80
222 Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada. J Int Assoc Provid AIDS Care 2013 0.79
223 Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000. AIDS 2003 0.79
224 Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. AIDS 2013 0.79
225 Including Online-Recruited Seeds: A Respondent-Driven Sample of Men Who Have Sex With Men. J Med Internet Res 2016 0.79
226 Implications for HIV prevention: lesbian, gay and bisexual adolescents in urban South Africa are at increased risk of living with HIV. Pediatr Infect Dis J 2013 0.79
227 "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice. PLoS One 2011 0.79
228 Factors predictive of 30-day postoperative mortality in HIV/AIDS patients in the era of highly active antiretroviral therapy. Ann Surg 2012 0.78
229 Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. J Acquir Immune Defic Syndr 2002 0.78
230 Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply. AIDS 2008 0.78
231 Women's Health Care Utilization among Harder-to-Reach HIV-Infected Women ever on Antiretroviral Therapy in British Columbia. AIDS Res Treat 2012 0.78
232 Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. J Int Assoc Provid AIDS Care 2013 0.78
233 The adherence gap: a longitudinal examination of men's and women's antiretroviral therapy adherence in British Columbia, 2000-2014. AIDS 2017 0.77
234 Social-structural factors associated with supportive service use among a cohort of HIV-positive individuals on antiretroviral therapy. AIDS Care 2013 0.77
235 Prescribing practices in a population-based HIV postexposure prophylaxis program. AIDS 2002 0.77
236 Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy. Antivir Ther 2006 0.77
237 Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Eur J Gastroenterol Hepatol 2011 0.77
238 Factors associated with buying and selling syringes among injection drug users in a setting of one of North America's largest syringe exchange programs. Subst Use Misuse 2006 0.77
239 Similar sexual behaviors with casual partners among gay men with and without a regular partner. Sex Transm Dis 2005 0.77
240 The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a Canadian setting. AIDS Care 2013 0.76
241 Exploring the role of sex-seeking apps and websites in the social and sexual lives of gay, bisexual and other men who have sex with men: a cross-sectional study. Sex Health 2016 0.76
242 High rates of lifetime and recent violence observed among harder-to-reach women living with HIV. AIDS Care 2013 0.76
243 An Event-Level Analysis of Condom Use During Anal Intercourse Among Self-Reported Human Immunodeficiency Virus-Negative Gay and Bisexual Men in a Treatment as Prevention Environment. Sex Transm Dis 2016 0.75
244 Effects of CCR5-delta32 and CCR2-641 alleles on HIV-1 disease progression: the protection varies with duration of infection, by Mulherin et al. AIDS 2003 0.75
245 Reduction of HIV incidence in men who have sex with men. Lancet Infect Dis 2010 0.75
246 Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs. Curr Opin HIV AIDS 2016 0.75
247 Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania Pujades, by Rodríguez et al. AIDS 2003 0.75
248 Risks for HIV and other sexually transmitted infections among Asian men who have sex with men in Vancouver, British Columbia: a cross-sectional survey. BMC Public Health 2013 0.75
249 Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants, by Dowling et al. AIDS 2003 0.75
250 The population impact of eliminating homelessness on HIV viral suppression among people who use drugs. AIDS 2016 0.75
251 Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study. AIDS Res Ther 2011 0.75
252 Fast track to Atlantis. J Urban Health 2003 0.75
253 The Continuum of HIV Care in Rural Communities in the United States and Canada: What Is Known and Future Research Directions. J Acquir Immune Defic Syndr 2017 0.75
254 Rates and predictors of injury in a population-based cohort of people living with HIV. AIDS 2017 0.75
255 Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada. Can J Public Health 2017 0.75
256 Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence. AIDS 2004 0.75
257 Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J Infect Dis 2003 0.75
258 Assessing the impact of an adult day program on hospital utilization by persons living with HIV/AIDS. J Acquir Immune Defic Syndr 2002 0.75
259 Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy. Rev Invest Clin 2004 0.75
260 Increasing HIV treatment optimism but no changes in HIV risk behaviour among men who have sex with men (MSM) in Vancouver, Canada. J Acquir Immune Defic Syndr 2017 0.75
261 Length of ICU stay for chronic obstructive pulmonary disease varies among large community hospitals. Intensive Care Med 2003 0.75
262 Is "3 by 5" enough? Recalculating the global need for antiretroviral treatment. Lancet 2004 0.75
263 Rates and predictors of injury in a population-based cohort of people living with HIV: trends and disparities from 1996 to 2013. AIDS 2016 0.75
264 The gender gap: a longitudinal examination of men's and women's art adherence in british columbia, 2000-2014. AIDS 2017 0.75
265 Random venous lactate levels among HIV-positive patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2002 0.75